Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALK201 in Advanced Solid Tumors
NCT06656390Phase 2Recruiting
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of ALK201 in solid tumor (advanced stage), sponsored by Shanghai Allink Biotherapeutics Co., Ltd. Primary endpoints: Safety and tolerability of ALK201 at 36 months, Maximum Tolerated Dose at 36 months and 1 more. Started Oct 2024; status: recruiting.
02
Drugs
ALK201
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06656390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06656390.